Cover Image
市場調查報告書

神經復健設備市場:各產品(神經機器人,腦電腦介面,穿戴式設備,非侵入性刺激器),各治療領域(中風,多發性硬化症,帕金森氏症,腦損傷性麻痺,其他),及市場區隔預測

Neurorehabilitation Devices Market By Products (Neurorobotics, Brain-Computer Interface, Wearable Devices, Noninvasive Stimulators), By Therapy Area (Stroke, Multiple Sclerosis, Parkinson's Disease, Cerebral Palsy, Others), & Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 374611
出版日期 內容資訊 英文 66 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經復健設備市場:各產品(神經機器人,腦電腦介面,穿戴式設備,非侵入性刺激器),各治療領域(中風,多發性硬化症,帕金森氏症,腦損傷性麻痺,其他),及市場區隔預測 Neurorehabilitation Devices Market By Products (Neurorobotics, Brain-Computer Interface, Wearable Devices, Noninvasive Stimulators), By Therapy Area (Stroke, Multiple Sclerosis, Parkinson's Disease, Cerebral Palsy, Others), & Segment Forecasts To 2024
出版日期: 2016年10月04日 內容資訊: 英文 66 Pages
簡介

本報告提供全球神經復健設備市場相關調查,市場概要和今後預測,彙整各市場區隔及地區別趨勢,及加入此市場的主要企業簡介等資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 市場概要

第4章 市場變動,趨勢,及範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 滲透及成長預測製圖
  • SWOT分析
  • 產業分析:波特五力分析

第5章 市場類別1:各產品預測與趨勢分析

  • 神經復健設備市場:各產品趨勢分析
  • 神經機器人
  • 腦電腦介面
  • 穿戴式設備
  • 非侵入性刺激器

第6章 市場類別2:各治療領域預測與趨勢分析

  • 神經復健設備市場:各治療領域趨勢分析
  • 中風
  • 多發性硬化症
  • 帕金森氏症
  • 腦損傷性麻痺
  • 其他

第7章 市場類別3:各地區預測及趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • 策略架構
  • 市場進入分類
目錄
Product Code: GVR-1-68038-139-9

The global neurorehabilitation devices market in 2015 was valued at USD 915.1 million and is estimated to reach USD 3.2 billion by 2024. Around 1 billion people are suffering from neurological disorders across the globe. These neurological disorders are resulting in increased movement disabilities. The increasing prevalence of movement disability, attributed to various neurological disorders (multiple sclerosis, stroke, etc) along with need for comprehensive management is the key factors driving the market growth.

Every year around 15 million people suffer from stroke globally, of which 5 million people are affected by permanent disability. Each year Multiple sclerosis and Parkinson's disease affect 2.5 million and 10 million patients respectively worldwide. The increasing prevalence and incidence rates of neurological disorders create a huge demand for neurorehab devices, as they ensure simplification of routine tasks for the disabled patients by reducing their dependency on others.

Furthermore, the rising awareness of neurorehab services among the care providers is contributing to the increasing adoption of these devices. In addition, consistent technological advancements are leading to introduction and commercialization of novel products in this sector. Majority of the manufacturers and distributors of neurorehab platforms are headquartered in North America region. North America dominates the market followed by Europe attributed to the rising awareness and increased adoption of novel technologies in these regions. Asia Pacific is growing at the highest CAGR among all the regions due to increasing target population and improving healthcare infrastructure.

Despite fluctuating economic conditions across different geographical regions coupled with the respective regulatory pressures, the companies offering neurorehab devices and services are exhibiting adaptability and efficacy. Some of the key market players are Bioness, Inc., Ectron Ltd., Hocoma AG, Medtronic, and Tyromotion. Collaborations for novel product development and strengthening of distribution networks constitute some of the strategic initiatives implemented by key players. For instance, Ectron Ltd. has collaborated with Bioness, Inc. and Tyromotion for distribution of their products across different geographical regions.

Further Key Findings From the Study Suggest:

Neurorobotics is expected to be one of the most lucrative segments in the coming years owing to the high availability of exoskeletons and prosthetics targeted for treating movement disabilities. Bioness, Inc. and Hocoma AG are few of the key manufacturers of exoskeletons and prosthetics.

Consistent technological sophistications in brain stimulations and machine learning brain-computer interface segment is expected to develop tremendously.

Non invasive stimulators have the potential to modulate brain plasticity. In February 2016, USFDA approved Medtronic's brain stimulation therapy in the treatment of Parkinson's disease.

Table of Content

Chapter 1: Research Methodology & Scope

  • 1.1. Region Wise Market Calculation
    • 1.1.1. Region Wise Market: Base Estimates
    • 1.1.2. Global Market: CAGR Calculation
  • 1.2. Region based segment share calculation
  • 1.3. List of Secondary Sources

Chapter 2: Executive Summary

Chapter 3: Market Snapshot

Chapter 4: Market Variables, Trends & Scope

  • 4.1. Market segmentation & scope
    • 4.1.1. Market Driver Analysis
      • 4.1.1.1. Increasing prevalence and incidence rates of neurological disorders
      • 4.1.1.2. Rise in geriatric population worldwide
      • 4.1.1.3. Technological advancements
    • 4.1.2. Market Restraint Analysis
      • 4.1.2.1. Unavailability of personalized home care neurorehabilitation devices
      • 4.1.2.2. Insufficient disposable income in developing countries
  • 4.2. Penetration & growth prospect mapping
  • 4.3. Neurorehabilitation Devices Market-SWOT Analysis, By Factor(political & legal, economic and technological)
  • 4.4. Industry Analysis-Porter's

Chapter 5: Market Categorization 1: Product Estimates & Trend Analysis

  • 5.1. Neurorehabilitation Devices market: Product movement analysis
  • 5.2. Neurorobotics
    • 5.2.1. Neurorobotics market estimates and forecasts, 2013-2024(USD Million)
  • 5.3. Brain-computer interface
    • 5.3.1. Brain-computer interface market estimates and forecasts, 2013-2024(USD Million)
  • 5.4. Wearable devices
    • 5.4.1. Wearable devices market estimates and forecasts, 2013-2024(USD Million)
  • 5.5. Non-invasive Stimulators
    • 5.5.1. Non-invasive Stimulators market estimates and forecasts, 2013-2024(USD Million)

Chapter 6: Market Categorization 2: Therapy Area Estimates & Trend Analysis

  • 6.1. Neurorehabilitation Devices market: Therapy Areas movement analysis
  • 6.2. Stroke
    • 6.2.1. Stroke marketestimates and forecasts, 2013-2024(USD Million)
  • 6.3. Multiple Sclerosis
    • 6.3.1. Multiple Sclerosis market estimates and forecasts, 2013-2024(USD Million)
  • 6.4. Parkinson's Disease
    • 6.4.1. Parkinson's Disease market estimates and forecasts, 2013-2024(USD Million)
  • 6.5. Cerebral Palsy
    • 6.5.1. Cerebral Palsy market estimates and forecasts, 2013-2024(USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2013-2024(USD Million)

Chapter 7: Market Categorization 3: Regional Estimates & Trend Analysis, by Product & Therapy Areas

  • 9.1. Neurorehabilitation Devices market share by region, 2013 & 2024
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. UK
    • 9.3.2. Germany
  • 9.4. Asia Pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. India
  • 9.5. Latin America
    • 9.5.1. Mexico
    • 9.5.2. Brazil
  • 9.6. MEA
    • 9.6.1. South Africa

Chapter 10: Competitive Landscape

  • 10.1. Strategy framework
  • 10.2. Market participation categorization
  • 10.3. Company Profiles
    • 10.3.1. Biometrics Ltd
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Product Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Bioness, Inc.
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Product Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Bionik Laboratories Corp.(BNKL)
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Product Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Bioxtreme Robotics Rehabilitation
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Ectron Ltd
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Ekso Bionics
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Hocoma AG
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Kinestica
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Kinova Robotics
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Medtronic PLC
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. NINET
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Product Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Saebo Ltd
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Product Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. St. Jude Medical
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Product Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Tyromotion
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Product Benchmarking
      • 10.3.14.4. Strategic Initiatives

List of Tables

  • TABLE 1: Country share estimation
  • TABLE 2: North America neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 3: North America neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 4: U.S. neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 5: U.S. neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 6: Canada neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 7: Canada neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 8: Europe neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 9: Europe neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 10: UK neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 11: UK neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 12: Germany neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 13: Germany neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 14: Asia Pacific neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 15: Asia Pacific neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 16: Japan neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 17: Japan neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 18: China neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 19: China neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 20: India neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 21: India neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 22: Latin America neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 23: Latin America neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 24: Mexico neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 25: Mexico neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 26: Brazil neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 27: Brazil neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 28: MEA neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 29: MEA neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)
  • TABLE 30: South Africa neurorehabilitation devices market, by product, 2013 - 2024 (USD Million)
  • TABLE 31: South Africa neurorehabilitation devices market, by therapy areas, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Market summary
  • FIG. 2: Market trends & outlook
  • FIG. 3: Neurorehabilitation devices : Market Segmentation
  • FIG. 4: Market driver relevance analysis (Current & future impact)
  • FIG. 5: Market restraint analysis (Current & future impact)
  • FIG. 6: Penetration & growth prospect mapping
  • FIG. 7: SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8: Neurorehabilitation devices Porter's analysis
  • FIG. 9: Neurorehabilitation devices market product outlook key takeaways
  • FIG. 10: Neurorehabilitation devices market: product movement analysis
  • FIG. 11: Neurorobotics market, 2013 - 2024 (USD Million)
  • FIG. 12: Brain-computer interface market, 2013 - 2024 (USD Million)
  • FIG. 13: Wearable devices market, 2013 - 2024 (USD Million)
  • FIG. 14: Non-invasive stimulators market, 2013 - 2024 (USD Million)
  • FIG. 15: Neurorehabilitation devices market therapy areas outlook key takeaways
  • FIG. 16: Neurorehabilitation devices market: Therapy areas movement analysis
  • FIG. 17: Stroke market, 2013 - 2024 (USD Million)
  • FIG. 18: Multiple Sclerosis market, 2013 - 2024 (USD Million)
  • FIG. 19: Parkinson's disease market, 2013 - 2024 (USD Million)
  • FIG. 20: Cerebral Palsy market, 2013 - 2024 (USD Million)
  • FIG. 21: Global others market, 2013 - 2024 (USD Million)
  • FIG. 22: Regional market place: Key takeaways
  • FIG. 23: Regional outlook, 2015 & 2024
  • FIG. 24: Strategy framework
  • FIG. 25: Participant categorization
Back to Top